Get access

Hyperbaric oxygen therapy for vascular dementia

  • Review
  • Intervention




Hyperbaric oxygen therapy (HBOT) has been used to treat a variety of conditions and has shown possible efficacy for treating vascular dementia (VaD) in experimental and preliminary clinical studies.


To assess the efficacy and safety of HBOT for VaD, used alone or as an adjuvant treatment.

Search methods

We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group Specialised Register on 20 December 2011 using the terms: hyperbaric OR oxygen OR HBO OR HBOT. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases, numerous trial registries and grey literature sources. We also searched the Chinese Biomedical Database (CBM), the Chinese National Knowledge Infrastructure (CNKI) and the VIP Chinese Science and Technique Journals Database on 10 November 2011 using the terms 'gaoyayang', 'xueguanxingchidai' and 'chidai'. In addition, we contacted authors of included studies for additional information.

Selection criteria

Trials were eligible for inclusion if they were randomised controlled trials comparing HBOT to no intervention or to sham HBOT, or comparing HBOT plus another treatment to the same other treatment in patients with VaD.

Data collection and analysis

Two review authors independently assessed trial quality and extracted data.

Main results

One study involving 64 patients was included. It compared HBOT as an adjuvant to donepezil with donepezil alone. This one included study was judged to be of poor methodological quality. Patients receiving HBOT plus donepezil had significantly better cognitive function than the donepezil only group after 12 weeks of treatment, measured by the Mini-Mental State Examination (MMSE) (WMD 3.50; 95% CI 0.91 to 6.09) or by Hasegawa's Dementia Rating Scale (HDS) (WMD 3.10; 95% CI 1.16 to 5.04). There were no deaths or withdrawals, and the study did not mention safety assessment at all. Global function, behavioral disturbance and activities of daily living were not investigated in the study.

Authors' conclusions

There is insufficient evidence to support HBOT as an effective treatment for patients with VaD. Future trials should be randomised, double-blind comparisons of HBOT to sham HBOT.








'hyperbaric'または'oxygen'または'HBO'または'HBOT'の用語を用い、2011年12月20日にALOIS: the Cochrane Dementia and Cognitive Improvement Group Specialised Registerを検索した。ALOISは、多数の主要な医療データベース、多くの試験登録リストおよび灰色文献を毎月検索して同定した臨床試験の記録を収載している。また、 'gaoyayang'、'xueguanxingchidai'、'chidai'の単語を用いて2011年11月10日にChinese Biomedical Database (CBM)、Chinese National Knowledge Infrastructure (CNKI)、VIP Chinese Science and Technique Journals Databasを検索した。さらに、その後追加された情報について選択した研究の著者に連絡を取った。






患者64名を対象とした1件の研究を選択した。それはドネペジルのアジュバントとしてのHBOTをドネペジル単独と比較するものであった。この選択した研究は方法論的に質が良くないと判断された。HBOT+ドネペジルを投与された患者はドネペジル単独療法群に比べて、Mini-Mental State Examination (MMSE)(WMD 3.50、95% CI 0.91~6.09)または長谷川式簡易知能評価スケール(HDS)(WMD 3.10、95% CI 1.16~5.04)により測定した治療12週間後の認知機能が有意に良好となった。死亡例および中止例はなく、研究では安全性の評価にについて全く言及されていなかった。全般的機能、行動障害、日常生活動作は本研究で検討されていなかった。



Plain language summary

Hyperbaric oxygen therapy for vascular dementia

Hyperbaric oxygen therapy (HBOT) has been used to treat a variety of conditions and has shown possible efficacy for treating vascular dementia (VaD) in experimental and preliminary clinical studies. This review included one randomised controlled trial of poor methodological quality involving 64 patients with VaD who were also taking donepezil. Safety assessment was not mentioned at all. Although the authors reported cognitive benefit, this trial alone cannot be taken as evidence of efficacy. Further well-designed randomised controlled trials are needed.





監  訳: 大神 英一,2012.11.14

実施組織: 厚生労働省委託事業によりMindsが実施した。

ご注意 : この日本語訳は、臨床医、疫学研究者などによる翻訳のチェックを受けて公開していますが、訳語の間違いなどお気づきの点がございましたら、Minds事務局までご連絡ください。Mindsでは最新版の日本語訳を掲載するよう努めておりますが、編集作業に伴うタイム・ラグが生じている場合もあります。ご利用に際しては、最新版(英語版)の内容をご確認ください。

Laički sažetak

Terapija hiperbaričnim kisikom za vaskularnu demenciju

Terapija hiperbaričnim kisikom (HBOT) se koristi za liječenje različitih stanja i pokazala je moguću učinkovitost u liječenju vaskularne demencije (VaD), u eksperimentalnim i preliminarnim kliničkim istraživanjima. Ovaj Cochrane sustavni pregled uključuje jedno randomizirano kontrolirano istraživanje loše metodološke kvalitete s 64 bolesnika s VaD-om koji su uzimali i donepezil. Ocjena sigurnosti uopće nije bila navedena. Iako su autori naveli rezultate o korisnim učincima na kognitivnu funkciju, samo ovo istraživanje ne može se uzeti kao dokaz učinkovitosti. Potrebna su daljnja dobro osmišljena randomizirana kontrolirana istraživanja.

Bilješke prijevoda

Cochrane Hrvatska
Prevela: Katarina Vučić
Ovaj sažetak preveden je u okviru volonterskog projekta prevođenja Cochrane sažetaka. Uključite se u projekt i pomozite nam u prevođenju brojnih preostalih Cochrane sažetaka koji su još uvijek dostupni samo na engleskom jeziku. Kontakt:

Get access to the full text of this article